/ Active, not recruiting临床3期 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Oral Epalrestat Therapy in Pediatric Subjects With Phosphomannomutase 2-congenital Disorder of Glycosylation (PMM2-CDG)
This is a prospective, single-center, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and clinical and metabolic improvement of pediatric subjects with PMM2-CDG on oral epalrestat therapy vs. placebo.
100 项与 Maggie's Pearl, LLC 相关的临床结果
0 项与 Maggie's Pearl, LLC 相关的专利（医药）
100 项与 Maggie's Pearl, LLC 相关的药物交易
100 项与 Maggie's Pearl, LLC 相关的转化医学
